Why the rapid development of new drugs poses new challenges
The origin and work of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
How far are we from a cure for CLL?
Lymphoma highlights from EHA 2016